ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Two-Part phase 1 / 2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) opr Philadelphia Chromosome Positive Acute Lymhoblastic leukemia (Ph+ALL)
EudraCT number 2016-001754-18
Protocol number CLR_15_03
Sponsor Sun Pharma Advanced Research Company Ltd., 17-B Mahal Industrial Estate, Mahakali Caves Road Andheri, Mumbai 400093, India
Indications Hemato-oncology
Diagnosis Chronic Myeloid Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2017
Date of approval by Institute (SÚKL) 10.5.2017
Date of approval by EC 7.6.2017
Date of initiation CT in ČR nezahájena
Date of ending CT in ČR 6. 6. 2019
Sites Fakultní nemocnice Brno, Interní hematologická a onkologická klinika, Jihlavská 20, 625 00 Brno

‹‹ Back to list